Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The goals of this clinical research study are to learn the tolerable and effective doses of
the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex
(fulvestrant) to patients with hormone receptor-positive metastatic breast cancer. The safety
of these drugs will be studied as well as markers in the tumors that may help researchers
predict the tumors' reaction to the treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb Commonwealth Foundation for Cancer Research Merck Sharp & Dohme Corp.